Zobrazeno 1 - 10
of 162
pro vyhledávání: '"Romualdo Barroso Sousa"'
Autor:
Fábio Fernandes Neves, Romualdo Barroso Sousa, Antônio Pazin-Filho, Palmira Cupo, Jorge Elias Júnior, Marcello Henrique Nogueira-Barbosa
Publikováno v:
Jornal Brasileiro de Pneumologia, Vol 36, Iss 4, Pp 513-516 (2010)
O paraquat é um herbicida não seletivo que possui grande importância toxicológica, sendo associado a altas taxas de letalidade, devidas principalmente à insuficiência respiratória. Este é o relato do caso de um homem de 22 anos admitido no de
Externí odkaz:
https://doaj.org/article/18e899233e054f70bb935820674bb8af
Autor:
Paolo Tarantino, Hersh Gupta, Melissa E. Hughes, Janet Files, Sarah Strauss, Gregory Kirkner, Anne-Marie Feeney, Yvonne Li, Ana C. Garrido-Castro, Romualdo Barroso-Sousa, Brittany L. Bychkovsky, Simona DiLascio, Lynette Sholl, Laura MacConaill, Neal Lindeman, Bruce E. Johnson, Matthew Meyerson, Rinath Jeselsohn, Xintao Qiu, Rong Li, Henry Long, Eric P. Winer, Deborah Dillon, Giuseppe Curigliano, Andrew D. Cherniack, Sara M. Tolaney, Nancy U. Lin
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-10 (2023)
Abstract The molecular underpinnings of HER2-low and HER2-0 (IHC 0) breast tumors remain poorly defined. Using genomic findings from 1039 patients with HER2-negative metastatic breast cancer undergoing next-generation sequencing from 7/2013-12/2020,
Externí odkaz:
https://doaj.org/article/5c5258c1093e4d42ab2f76c5fe3ba511
Autor:
Gil Cunha De Santis, Mirela de Barros Tamarozzi, Romualdo Barroso Sousa, Susana Elisa Moreno, Daniela Secco, Aglair Bergamo Garcia, Ana Sílvia Gouveia Lima, Lúcia Helena Faccioli, Roberto Passetto Falcão, Fernando Queirós Cunha, Eduardo Magalhães Rego
Publikováno v:
Haematologica, Vol 92, Iss 12 (2007)
Background and Objectives Differentiation Syndrome (DS) is a treatment complication which can occur in patients treated with acute promyelocytic leukemia (APL) with all transretinoic acid (ATRA) or As2O3, and is characterized by enhanced leukocyte tr
Externí odkaz:
https://doaj.org/article/0a385569140a48568f870e22a8a334a4
Autor:
Sarah Sammons, Andrew Elliott, Romualdo Barroso-Sousa, Saranya Chumsri, Antoinette R. Tan, George W. Sledge, Sara M. Tolaney, Evanthia T. Roussos Torres
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundData supporting high tumor mutational burden (TMB-H) as a lone biomarker for an immune-responsive tumor microenvironment (TME) in metastatic breast cancer (MBC) are weak, yet tumor agnostic approval in TMB-H advanced tumors provides immune
Externí odkaz:
https://doaj.org/article/8b0d35ab3ce5400f8a02d8f094918d24
Autor:
Romualdo Barroso-Sousa, Paolo Tarantino, Nabihah Tayob, Chau Dang, Denise A. Yardley, Steven J. Isakoff, Vicente Valero, Meredith Faggen, Therese Mulvey, Ron Bose, Jiani Hu, Douglas Weckstein, Antonio C. Wolff, Katherine Reeder-Hayes, Hope S. Rugo, Bhuvaneswari Ramaswamy, Dan Zuckerman, Lowell Hart, Vijayakrishna K. Gadi, Michael Constantine, Kit Cheng, Frederick Briccetti, Bryan Schneider, Audrey Merrill Garrett, Kelly Marcom, Kathy Albain, Patricia DeFusco, Nadine Tung, Blair Ardman, Rita Nanda, Rachel C. Jankowitz, Mothaffar Rimawi, Vandana Abramson, Paula R. Pohlmann, Catherine Van Poznak, Andres Forero-Torres, Minetta Liu, Kathryn J. Ruddy, Yue Zheng, Shoshana M. Rosenberg, Richard D. Gelber, Lorenzo Trippa, William Barry, Michelle DeMeo, Harold Burstein, Ann Partridge, Eric P. Winer, Ian Krop, Sara M. Tolaney
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-7 (2022)
Abstract The excellent outcomes seen in patients treated with adjuvant trastuzumab emtansine (T-DM1) in the ATEMPT trial and the favorable toxicity profile associated with this agent make T-DM1 a potential therapeutic option for select patients with
Externí odkaz:
https://doaj.org/article/e88fcc1488804534afd42026e28dc869
Autor:
Marcello Moro Queiroz, Karina Perez Sacardo, Mauricio Fernando Ribeiro, Luiza Lara Gadotti, Rodrigo Saddi, Leandro Jonata de Carvalho Oliveira, Rudinei Diogo Marques Linck, Marcelo Rocha de Souza Cruz, Romualdo Barroso-Sousa, Marina Sahade, Tatiana Strava Correa, Max Senna Mano, Daniele Assad Suzuki, Andrea Kazumi Shimada, Artur Katz
Publikováno v:
Cancer Treatment and Research Communications, Vol 35, Iss , Pp 100683- (2023)
Background: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have been recently developed and introduced into clinical practice. Methods: We retrospectively analyzed data from patients with confirmed HR+/HER2 metastatic breast cancer treated with hor
Externí odkaz:
https://doaj.org/article/f00841e7cf3c4c4fa3e29cdc2d34613b
Autor:
Maria Paula Furtado Santos, Allan Andersson Lima Pereira, Luiza Nardin Weis, Ana Carolina de Aquino Diniz, Rodrigo Bovolin de Medeiros, Artur Katz, Igor Alexandre Protzner Morbeck, Gustavo dos Santos Fernandes, Rodrigo Ramela Munhoz, Romualdo Barroso-Sousa
Publikováno v:
Brazilian Journal of Oncology, Vol 18, Iss 00 (2022)
Objectives: To report real-world data of a cohort of patients treated with immune-checkpoint inhibitors in Brazil, with focus in immune-related adverse events. Material and Methods: In this retrospective study, we analyzed a cohort of patients wit
Externí odkaz:
https://doaj.org/article/1dcef85cf2eb4b6b9bbef35b89c5d451
Autor:
Leandro Jonata Carvalho Oliveira, Thais Baccili Cury Megid, Daniela Dornelles Rosa, Carlos Alberto da Silva Magliano, Daniele Xavier Assad, Daniel Fontes Argolo, Solange Moraes Sanches, Laura Testa, José Bines, Rafael Kaliks, Maira Caleffi, Debora de Melo Gagliato, Marina Sahade, Romualdo Barroso-Sousa, Tatiana Strava Corrêa, Andrea Kazumi Shimada, Daniel Negrini Batista, Daniel Musse Gomes, Marcelle Goldner Cesca, Débora Gaudêncio, Larissa Matos Almeida Moura, Julio Antonio Pereira de Araújo, Artur Katz, Max Senna Mano
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Background: Oncotype DX (ODX) is a validated assay for the prediction of risk of recurrence and benefit of chemotherapy (CT) in both node negative (N0) and 1–3 positive nodes (N1), hormone receptor positive (HR+), human epidermal growth factor rece
Externí odkaz:
https://doaj.org/article/bf12e41b48ea42f997e8e48720fed3f0
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-9 (2021)
Abstract Precision medicine has provided new perspectives in oncology, yielding research on the use of targeted therapies across different tumor types, regardless of their site of origin, a concept known as tissue-agnostic indication. Since 2017, the
Externí odkaz:
https://doaj.org/article/99ddf49ec2724697925a230a9dd6ae2f
Autor:
Tanya E. Keenan, Jennifer L. Guerriero, Romualdo Barroso-Sousa, Tianyu Li, Tess O’Meara, Anita Giobbie-Hurder, Nabihah Tayob, Jiani Hu, Mariano Severgnini, Judith Agudo, Ines Vaz-Luis, Leilani Anderson, Victoria Attaya, Jihye Park, Jake Conway, Meng Xiao He, Brendan Reardon, Erin Shannon, Gerburg Wulf, Laura M. Spring, Rinath Jeselsohn, Ian Krop, Nancy U. Lin, Ann Partridge, Eric P. Winer, Elizabeth A. Mittendorf, David Liu, Eliezer M. Van Allen, Sara M. Tolaney
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
A randomized phase 2 clinical trial has recently shown no benefit of the combination eribulin and pembrolizumab over pembrolizumab alone in HR + metastatic breast cancer patients (NCT03051659). Here, the authors are reporting the final OS data and bi
Externí odkaz:
https://doaj.org/article/d25f24d7eb06482f96ec27595b0111bc